A Multifunctional Electrospun Hemostatic Sponge for Effective Wound Closure and Healing
Source abstract
Abstract
Uncontrolled hemorrhage following severe trauma necessitates hemostatic agents capable of not only instantaneous clotting but also pro-healing functionality. To bridge this gap, we engineered a dual-release fibrous sponge (ULOCa-T) via an integrated electrospinning-electrospraying strategy. This design synergistically leverages surface-immobilized thrombin for immediate hemostatic activation and sequentially released calcium chloride (CaCl 2 ) from a hygroscopic thermoplastic polyurethane (TPU)/polycaprolactone (PCL)/hydrophilic poly(ethylene oxide) (PEO) matrix to amplify the coagulation cascade. In a rat liver injury model, ULOCa-T achieved effective hemostasis within 157 s─a 57% reduction compared to controls─and drastically cut blood loss to 48.16 mg. Beyond its superabsorbent capacity (12× its dry weight), the sponge demonstrated multifaceted bioactivity: it promoted platelet activation, downregulated key pro-inflammatory cytokines (IL-1β and TNF-α), and enhanced the expression of regeneration markers (VEGF and CD31), collectively accelerating wound closure. Owing to its straightforward fabrication and ready-to-use nature, ULOCa-T presents a transformative potential for managing trauma and surgical bleeding.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemostasis and retained surgical items · Electrospun Nanofibers in Biomedical Applications · Wound Healing and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Polymeric and Soft Materials Laboratory, School of Chemistry and Life Science, Advanced Institute of Materials Science
Changchun University of Technology
The Second Hospital of Jilin University
Advanced Institute of Materials Science, School of Chemical Engineering
Biodiscovery Institute
University of Nottingham
Department of Chemical and Environmental Engineering and School of Pharmacy
Funding
AO Foundation · Department of Science and Technology of Jilin Province · China Scholarship Council
References (54)
Show source-provided references
1. 10.1002/adma.20170085910.1002/adma.201700859 ↗
2. 10.1039/D2SC04962G10.1039/D2SC04962G ↗
3. 10.1016/j.bioactmat.2020.05.00810.1016/j.bioactmat.2020.05.008 ↗
4. 10.1038/s41570-021-00323-z10.1038/s41570-021-00323-z ↗
5. 10.1016/j.bioactmat.2023.01.01910.1016/j.bioactmat.2023.01.019 ↗
6. 10.1021/acsami.9b1773210.1021/acsami.9b17732 ↗
7. 10.1002/adfm.20221134010.1002/adfm.202211340 ↗
8. 10.1002/adhm.20210091810.1002/adhm.202100918 ↗
9. 10.1002/adma.20230184910.1002/adma.202301849 ↗
10. 10.3390/pharmaceutics1504114410.3390/pharmaceutics15041144 ↗
11. 10.1186/s12951-023-01987-z10.1186/s12951-023-01987-z ↗
12. 10.1016/j.jconrel.2020.07.03810.1016/j.jconrel.2020.07.038 ↗
13. 10.1038/s41467-019-13512-810.1038/s41467-019-13512-8 ↗
14. 10.1016/j.ijbiomac.2022.07.18610.1016/j.ijbiomac.2022.07.186 ↗
15. 10.1007/s10570-020-03479-x10.1007/s10570-020-03479-x ↗
16. 10.2147/IJN.S7255310.2147/IJN.S72553 ↗
17. 10.1016/j.carbpol.2018.12.05610.1016/j.carbpol.2018.12.056 ↗
18. 10.1039/C9NR01477B10.1039/C9NR01477B ↗
19. 10.1021/acsami.9b1244410.1021/acsami.9b12444 ↗
20. 10.3390/pharmaceutics1312212710.3390/pharmaceutics13122127 ↗
21. 10.1002/adhm.20230346010.1002/adhm.202303460 ↗
22. 10.1007/s10853-023-09124-910.1007/s10853-023-09124-9 ↗
23. 10.1097/shk.000000000000064610.1097/shk.0000000000000646 ↗
24. Iso, I. 10993–5:2009 Biological Evaluation of Medical Devices─Part 5: Tests for in Vitro Cytotoxicity ; International Organization for Standardization: Geneva, 2009; 34.
25. 10.1007/s00240-024-01556-510.1007/s00240-024-01556-5 ↗
26. 10.1002/adhm.20230220910.1002/adhm.202302209 ↗
27. 10.1016/j.carbpol.2019.11500710.1016/j.carbpol.2019.115007 ↗
28. 10.1039/D3TB01900D10.1039/D3TB01900D ↗
29. 10.1016/j.ijbiomac.2021.02.16210.1016/j.ijbiomac.2021.02.162 ↗
30. 10.3390/ma1315325010.3390/ma13153250 ↗
31. 10.1016/j.ijbiomac.2023.12664210.1016/j.ijbiomac.2023.126642 ↗
32. 10.1016/j.ijbiomac.2023.12400410.1016/j.ijbiomac.2023.124004 ↗
33. 10.1021/acssuschemeng.6b0284910.1021/acssuschemeng.6b02849 ↗
34. 10.1016/j.thromres.2020.07.02710.1016/j.thromres.2020.07.027 ↗
35. 10.1039/D1MA00137J10.1039/D1MA00137J ↗
36. 10.1021/acsami.9b0879910.1021/acsami.9b08799 ↗
37. 10.1126/scitranslmed.301038310.1126/scitranslmed.3010383 ↗
38. 10.4103/0019-5049.14464310.4103/0019-5049.144643 ↗
39. 10.1002/adfm.20191074810.1002/adfm.201910748 ↗
40. 10.1039/C9SM01296F10.1039/C9SM01296F ↗
41. 10.1016/j.carbpol.2017.08.07010.1016/j.carbpol.2017.08.070 ↗
42. 10.1111/j.1538-7836.2007.02500.x10.1111/j.1538-7836.2007.02500.x ↗
43. 10.1016/j.nantod.2021.10116510.1016/j.nantod.2021.101165 ↗
44. 10.2174/138920102337828310.2174/1389201023378283 ↗
45. 10.1016/j.cej.2024.15054510.1016/j.cej.2024.150545 ↗
46. 10.2174/09298670978987821010.2174/092986709789878210 ↗
47. Singh D. · Cardiol Cardiovasc Med. · 2023 · 7 · 510.26502/fccm.92920302 ↗
48. 10.4049/jimmunol.163.7.396310.4049/jimmunol.163.7.3963 ↗
49. 10.1073/pnas.150962711210.1073/pnas.1509627112 ↗
50. DeLisser H. M. · Am. J. Pathol. · 1997 · 151 · 671
51. 10.1016/j.surg.2005.07.01010.1016/j.surg.2005.07.010 ↗
52. 10.1039/D2BM01767A10.1039/D2BM01767A ↗
53. 10.1016/j.eurpolymj.2021.11073310.1016/j.eurpolymj.2021.110733 ↗
54. 10.1039/C9TB00659A10.1039/C9TB00659A ↗